A previously unappreciated cell type of the innate immune system, termed innate lymphoid cells (ILCs), has been characterized in mice and humans and found to influence the induction, regulation and resolution of inflammation. ILCs have an important role in these processes in mouse models of infection, inflammation and tissue repair. Further, disease-association studies in defined patient populations have identified significant alterations in ILC responses, suggesting a potential role for these cell populations in human health and disease. In this review we discuss the emerging family of ILCs, the role of ILCs in inflammation, and how current or novel therapeutic strategies could be used to selectively modulate ILC responses and limit chronic inflammatory diseases.
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Inflammation is defined as heat, redness, pain, swelling and loss of function. Whereas acute inflammation is a necessary process to protect against infection and promote tissue repair, chronic inflammation directly contributes to the pathogenesis and progression of multiple infectious, inflammatory and metabolic disorders, including HIV/AIDS, inflammatory bowel disease, arthritis, psoriasis, allergy, asthma, diabetes, obesity and cancer 1, 2 . Although there are many well-characterized cellular and molecular components of the innate and adaptive immune system that influence inflammatory processes, recent characterization of an emerging family of innate immune cells, termed ILCs, has revealed an essential role for these populations in the initiation, regulation and resolution of inflammation. ILCs are innate lymphocytes that are relatively rare in comparison to adaptive lymphocytes in lymphoid tissues, but they are enriched at barrier surfaces of the mammalian body, such as the skin, lung and intestine, as well as in adipose and some mucosal-associated lymphoid tissues [3] [4] [5] [6] . ILCs rapidly respond to cytokine and microbial signals and are potent innate cellular sources of multiple pro-inflammatory and immunoregulatory cytokines, and recent research has also identified a crucial role for ILCs in modulating adaptive immunity. Mature ILC subsets can be identified by a lack of known lineage markers associated with T cells, B cells, myeloid cells, or granulocytes, but they share expression of the common gamma chain (γc, CD132), IL-7Rα (CD127), IL-2Rα (CD25), and Thy1 (CD90) markers, with some exceptions noted below [3] [4] [5] [6] .
A combination of advances in multi-parameter flow cytometry and the identification of novel cytokine pathways regulating immunity and inflammation-including the interleukin (IL)-23-IL-22 pathway [7] [8] [9] [10] [11] [12] and epithelial-derived cytokines IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) [13] [14] [15] [16] [17] -has contributed to our emerging knowledge of ILCs. Prototypical members of the ILC family were discovered many years ago, including the natural killer (NK) cells in 1975 (refs. 18,19) , and subsequently lymphoid tissue-inducer (LTi) cells 20 . However, it was not until more recently that other members of the ILC family were characterized. These characterizations included simultaneous reports of innate lymphocytes that are predominant cellular sources of the cytokines IL-17 and IL- 22 (refs. 21-28) or IL-5 and IL- 13 (refs. 29-33) in the steady state or early after infection. These rapid and fundamental advances also generated redundant nomenclature based on the functional potential of the identified cells, including NK-22 cells, LTi-like cells, natural helper cells, nuocytes and innate helper cells. To limit confusion, leaders in the field later unified a common terminology to classify these emerging cell populations as a new family of ILCs which encompasses three subsets, termed group 1, 2 or 3 ILCs, on the basis of common expression of surface markers, transcription factors and cytokines 3 .
Recent studies of ILCs have provoked a paradigm shift in our understanding of innate and adaptive immunity, and they have fueled additional extensive investigation into these cells because of the potential influence of ILCs in human health and disease. Mouse models indicate that ILCs have a fundamental role in the immune system by initiating, regulating and resolving inflammation. Further, studies in humans have revealed that ILC responses are substantially altered in several disease states. Below we discuss the development and heterogeneity of ILCs, the role of human and mouse ILCs in inflammatory processes, and how current or novel therapeutic strategies could be used to modulate ILC responses and benefit human health.
Development and heterogeneity of the ILC family
ILCs initially develop in the fetal liver and later in the adult bone marrow from common lymphoid progenitors (CLPs) [34] [35] [36] . CLPs also differentiate into cells of the adaptive immune system, such as T cells and B cells, but development of ILCs from CLPs occurs independently of somatic recombination, a defining feature of the adaptive immune system that permits the generation of antigen-specific receptors or secreted proteins such as the T cell receptor, B cell receptor and immunoglobulin. ILC development is regulated at the transcriptional level, with several precursor populations and transcription factors regulating each group (Fig. 1) 4, 37, 38 . Differentiation of all ILCs from a CLP requires the transcription factors inhibitor of DNA binding 2 (Id2), nuclear factor interleukin-3 regulated (NFIL3) 3, 4, 36, [39] [40] [41] [42] [43] , and thymocyte selection-associated high mobility group box (Tox) 44, 45 , and it involves additional precursor cell populations (Fig. 1) . These include NK cell precursors (NKps) that give rise to NK cells, as well as a common helper innate lymphoid precursor (CHILP) that gives rise to all other defined ILCs in a process that requires T cell factor 1 (TCF1) 46, 47 and GATA binding protein 3 (GATA3) 48, 49 . From CHILPs, several distinct progenitors expressing α4β7 integrin give rise to LTi cells 34 , whereas promyelocytic leukemia zinc finger (PLZF)-dependent ILC progenitors (ILCps) can give rise to other defined ILC subsets 35 . Although the specific interactions and functions of transcription factors in ILC development are not well defined, IL-7 signaling can induce NFIL3 and subsequently Id2 to support the generation of ILCps 39 . However, additional studies are required to further define these functional interactions, as NFIL3-deficient mice do not completely replicate the phenotype of Id2-deficient mice, which lack all ILCs. Further, although most of these developmental studies have necessarily used mice, CD34 + hematopoietic progenitor cells (HSCs) in the bone marrow or peripheral blood of humans can give rise to α4β7 integrin-expressing CD34 + progenitors in the lymphoid tissues and intestinal lamina propria, which have the potential to differentiate into either NK cells or LTi-like cells in a process that is influenced by the presence of aryl hydrocarbon receptor (Ahr) ligands, stem cell factor (SCF) and .
Mature ILCs provide a potent and early source of cytokines in response to various stimuli, including direct cytokine stimulation, or as a consequence of colonization with commensal microbes or pathogen infection. There is considerable phenotypic and functional heterogeneity in the mature ILC family, and broadly three groups of ILCs have been defined on the basis of shared expression of surface markers, transcription factors and effector cytokines (Fig. 1) [3] [4] [5] [6] .
Group 1 ILCs (ILC1s) respond to IL-12, constitutively express T-bet, and produce effector cytokines including interferon (IFN)-γ and tumor necrosis factor (TNF) 36, 51, 52 . ILC1s are considerably heterogeneous and can be distinguished into at least three subsets according to their differential expression and requirements for eomesodermin (eomes), T-bet, IL-15 and IL-7. Conventional NK cells are a subset of ILC1s requiring eomes and IL-15 for development from NKps, but not T-bet or IL-7 (ref. 36 ). ILC1s also include CD103 + intraepithelial ILC1s, which develop independently of IL-15 from an unknown precursor, express eomes, and require T-bet for differentiation 52 . Further, CD127 + ILC1s were also identified in humans and mice; they do not express eomes and develop independently of IL-7 from a CHILP and ILCp, but they require T-bet and IL- 15 (refs. 36,51) .
Group 2 ILCs (ILC2s) respond to the cytokines IL-25, IL-33 and TSLP; constitutively express high levels of GATA3; and produce the effector cytokines IL-4, IL-5, IL-9, IL-13 and amphiregulin [29] [30] [31] [32] [33] . Although GATA3 is required for the development of most ILC subsets 48, 49 , it is also required for the maintenance and function of mature ILC2s in humans and mice [53] [54] [55] [56] . RAR-related orphan receptor (ROR)-α is also required for ILC2 development in mice 57, 58 , but is also highly expressed by other ILC subsets and its function is poorly defined 59 . The transcription factors Gfi1 and Bcl11b also contribute to the differentiation or lineage stability of mouse ILC2s [60] [61] [62] . Although mature ILC2s can be found in most anatomical locations, they seem to be enriched in the healthy lung, skin and adipose tissue of mice and humans 29, 31, 32, [63] [64] [65] [66] .
Group 3 ILCs (ILC3s) respond to IL-1β, IL-6 and IL-23; constitutively express RORγt; and produce the effector cytokines IL-17 and/or IL- 22 (refs. 21-28) . Although all ILC3 share a developmental requirement for RORγt (refs. 24,67) , substantial heterogeneity exists within this group. Fetal and adult LTi cells are members of the ILC3 group, and they develop independently of PLZF-dependent ILCps, are CCR6 + , heterogeneous in expression of CD4, express IL-22 and IL-17, and are a source of lymphotoxin (LT). A subset of adult ILC3s can develop from PLZF-dependent ILCps after birth, are CCR6 − , co-express T-bet, are heterogeneous in expression of natural cytotoxicity receptors (NCRs, such as NKp46 and NKp44), and can co-express IL-22 and IFN-γ. This T-bet + ILC3 population requires T-bet, the presence of commensal bacteria and the Ahr for development [68] [69] [70] [71] [72] . T-bet + ILC3s are almost exclusively found in the skin and intestinal lamina propria, whereas LTi-like ILC3s are enriched in the r e v i e w 
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intestine and lymphoid tissues 28, 68, [73] [74] [75] . Further, as discussed below, ILC3s with a unique phenotype can develop in some inflammatory contexts in the intestine and liver 24, 76 . Some plasticity between ILC groups has been observed. ILC3 subsets can downregulate RORγt expression in mice and humans, resulting in a dominant expression of T-bet and sustained expression of 68, 72) . However, it is currently unclear whether to classify these populations as ILC1s or ILC3s, and it is difficult to distinguish them from a stable ILC1 lineage without fate-mapping approaches that genetically mark cells that express or previously expressed RORγt. Therefore, many groups have termed these cells ex-ILC3s (refs. 36,51,68,72) . Additional evidence suggests that a transient IL-25-responsive ILC2 population can differentiate into an IL-17-producing ILC3-like cell 77 , although additional research is required to fully characterize the extent of ILC plasticity, as well as to define the potential causes and consequences of this plasticity.
ILCs orchestrate acute inflammation to promote immunity to infection Acute inflammation is necessary to mount an effective immune response to various infectious organisms. ILCs were first identified on the basis of their ability to promote rapid and essential innate immune responses to different classes of pathogens, in part by modulating local epithelial cell, myeloid cell or granulocyte responses (Fig. 2 ).
ILC1s and intracellular pathogens. ILC1 populations have a crucial role in promoting immunity to intracellular pathogens (Fig. 2a) . Rapid NK cell responses have been well characterized after exposure to multiple intracellular pathogens in both humans and mice 78 . However, the role of other ILC1 populations has been less clear. Recent evidence suggests that ILC1s are the dominant innate source of IFN-γ and TNF in mice after infection with the oral pathogen Toxoplasma gondii, and that they have role in recruiting inflammatory myeloid cells that control infection 36 . Consistent with this, genomic T-bet deficiency rendered mice highly susceptible to T. gondii infection, and adoptive transfer of ILC1s to lymphocyte-deficient mice (Rag2 −/− Il2rg −/− ) was sufficient to boost immunity 36 .
ILC2s and extracellular parasites. ILC2s rapidly respond after exposure to multicellular parasites that are typically extracellular (Fig. 2b) . For example, ILC2s are an important innate cellular source of IL-13 in the intestine after infection of mice with the parasite Nippostrongylus brasiliensis 29, 30, 33 . IL-13 can act on goblet cells to induce mucus production, and on smooth muscle to enhance contractility, both of which are thought to contribute to expulsion of the parasites from the gastrointestinal tract 79 . IL-4 and IL-13 can also induce goblet cell expression of RELMβ, which limits parasitic infection 80 . Epithelial cell-derived IL-25 and IL-33 primarily promote the population expansion and cytokine production of ILC2s after parasite infection of mice 29, 30, 33 . ILC2s can similarly promote IL-13-mediated immunity to other parasites in mice, including Trichuris muris 81 . Notably, this response could be enhanced by vitamin A deficiency 81 , suggesting that ILC2s can respond to dietary stress and that the type 2 immune response may have adapted to support anti-parasite immunity in human populations with malnutrition.
ILC3s and extracellular bacteria and fungi. ILC3s rapidly respond to infection of mice with either extracellular bacteria or fungi (Fig. 2c) . NCR + ILC3s rapidly respond to infection of mice with the Gram-negative enteric pathogen Citrobacter rodentium by producing IL-22 (ref. 22) , which is essential for host protection 7 . These ILC3 responses in humans and mice can be promoted by dendritic cell (DC)-derived IL-23 (ref. 22) , and in mice ILC3 are a dominant and essential source of IL-22 for innate immunity to C. rodentium in the intestine 21, 23 . IL-22 acts almost exclusively on non-hematopoietic cells, such as intestinal epithelial cells (IECs), and it stimulates production of anti-microbial peptides (RegIIIγ and RegIIIβ), element-sequestering proteins (lipocalin-2, S100A8 and S100A9), mucus production (Muc1, 3, 10 and 13) and epithelial fucosylation (Fut2) 7-9,82-85 . These responses collectively limit the replication, dissemination and tissue damage induced by pathogenic and opportunistic bacteria. Similarly, ILC3s located in the oral mucosa promote IL-17-dependent innate immunity to infection with the fungal pathogen Candida albicans in mice 86 . IL-17 can act alone or synergistically with IL-22 to also promote antimicrobial peptide production, and it induces the expression 
of chemokines (Cxcl1 and Cxcl9) to recruit neutrophils to the site of infection [7] [8] [9] 87 . ILC3-derived IL-17 also regulates neutrophils in neonatal mice, which is important for resistance to sepsis with Gramnegative opportunistic bacteria and is dependent upon the presence of commensal bacteria 88 . Collectively, this suggests that the ILC family has a key role in mediating acute inflammation in response to infection, which is important for the control and clearance of various classes of pathogens.
ILCs promote the resolution of inflammation and tissue repair In addition to their role in initiating acute inflammatory responses and immunity to pathogens, ILCs directly contribute to the resolution of inflammation by repairing damaged tissues, including the lung, various lymphoid tissues, and the gastrointestinal tract (Fig. 3) . These repair processes are essential to limiting sustained inflammation, preventing re-infection and restoring tissues to a state of homeostasis.
ILC2s and resolution of inflammation in the lung. In the lung of mice, ILC2s are activated in response to IL-33 after influenza virus infection and subsequent immune-mediated tissue damage 31 ( Fig. 3a) .
Experimental depletion of ILC2s in mice did not impair innate immunity to influenza, but rather limited repair of the airway epithelium and reduced lung function. This repair function was not mediated by the responses of ILC2 cytokines, such as IL-13, but rather was promoted by production of amphiregulin, a member of the epidermal growth factor family that was highly expressed by ILC2s 31 . Further, after infection and subsequent tissue damage induced by the migration of N. brasiliensis in the lungs of mice, autocrine production of IL-9 contributes to the survival of ILC2s and was associated with amphiregulin production and repair of the lung tissues 89 . ILC2s therefore represent a major ILC population in the lung that promotes tissue repair after infection. Mouse ILC2s also promote cutaneous wound healing in an excisional wound model (D.A., unpublished data). Although it has been demonstrated that human ILC2s express amphiregulin at the transcript level 90 , additional work is needed to define whether human ILC2s are potent sources of amphiregulin and mediate tissue repair. Also, it currently remains unclear whether ILC2s can promote tissue repair at different anatomical locations.
ILC3s and resolution of inflammation in lymphoid tissues and the intestine. ILC3s promote tissue repair through several distinct mechanisms (Fig. 3b,c) . Systemic viral infections can impair the architecture of secondary lymphoid organs after CD8 + T cell-mediated killing of infected stromal cells 91 . 91 ( Fig. 3b) . Further, ILC3s can also promote tissue repair in the thymus of mice after total body irradiation 92 . In this context, CCR6 + ILC3s are partially radio-resistant and respond to irradiation-induced IL-23, promoting IL-22-dependent restoration of tissue integrity in the thymus 92 . IL-22 acts on thymic epithelial cells to promote cell survival and proliferation 92 . Further, IL-22-dependent tissue repair in mice has also been reported in the liver following chemical-induced hepatitis 79 and in the lung after influenza infection or bleomycin-induced damage 87, 93, 94 , which are two other organs in which the tissueresident non-hematopoietic cells highly express the IL-22 receptor 8 .
In the intestine, ILC3s have an important role in regulating tissue repair (Fig. 3c) . This may be particularly important in the context of human inflammatory bowel disease (IBD) because several reports have identified reduced numbers of ILC3s in intestinal tissues from disease patients relative to non-IBD controls 51, 95, 96 . In mouse models, production of IL-22 by ILC3s mediates tissue repair after experimental tissue damage induced by hematopoietic stem cell transplantation (HSCT) and subsequent graft-versus-host disease (GVHD), or after administration of dextran sodium sulfate (DSS) [97] [98] [99] . Following whole-body irradiation and HSCT, radio-resistant ILC3s respond to DC-derived IL-23 and produce IL-22. IL-22 acts on the intestinal 98 . If alloreactive T cells with the capacity to attack donor tissues are co-transferred into mice after irradiation, this causes GVHD and is associated with a decrease in intestinal ILC3s and enhanced intestinal tissue damage owing to a loss of . In humans, ILC3s are not normally observed in the circulation, but they are found after chemotherapy for HSCT 100 . Furthermore, the levels of circulating ILC3s positively correlate with a reduced incidence of developing GVHD 100 , suggesting a critical role for human ILC3s in limiting GVHD. In the DSS model of intestinal damage and inflammation, ILC3 responses and production of IL-22 also promote tissue repair and maintain intestinal barrier function 82, 97 . This process is regulated by commensal bacteria, which induce expression of IL-25 by IECs after colonization in the postnatal period 97, 101 . IL-25 acts on IL-25R + DCs to subsequently limit ILC3 responses in a contact-dependent manner 97 . However, upon induction of experimental tissue damage with DSS, IL-25 expression was reduced and ILC3 responses were enhanced relative to naive mice, increasing IL-22 production and tissue repair 97 . ILC3 responses and IL-22-dependent tissue repair can also be enhanced in mice and humans after recognition of pathogenic or commensal microbes by CX3CR1 + myeloid cells and subsequent production of IL-1β, IL-23 and TL1A (refs. 102-105) . One potential reason for the differential roles of commensal bacteria in promoting or suppressing ILC3 responses could be explained by the differential regulation of IL-1β secretion by pathogenic bacteria and selective subsets of commensal bacteria 106, 107 . The vitamin A metabolite retinoic acid (RA) can also enhance ILC3 responses in mice through multiple mechanisms, including direct binding to the Rorc or Il22 loci, promoting maturation of LTi-like ILC3s, and regulating ILC3 proliferation 81, 99, 108 . In addition to promoting maintenance of the intestinal epithelium, during fetal development vitamin A and the metabolite RA control the size of secondary lymphoid tissues via LTi cells in mice, which could influence the efficiency of protection from viral infections later in life 108 . Thus, ILC3s have a major role in repairing damaged lymphoid tissues, airway epithelia, liver, and intestinal epithelia, thus preserving organ function.
ILCs promote chronic inflammation
ILCs can also promote chronic inflammation in several mouse models, and dysregulated ILC responses have been characterized in patient populations with chronic inflammatory disease of the lung, skin and intestine (Fig. 4) .
ILC2s and chronic inflammation in the lung and skin. Increased ILC2 responses have been observed in multiple allergic diseases, including in the skin of individuals with atopic dermatitis 63, 90 , in the nasal polyps of individuals with chronic rhinosinusitis 32 , circulating in the blood of individuals with asthma 109 , and in the bronchalveolar lavage fluid of individuals with idiopathic pulmonary fibrosis 110 . In mouse models, dysregulated ILC2 responses contribute to chronic inflammation in the lung and skin (Fig. 4a) . For example, ILC2 responses are elicited by epithelial cell-or myeloid cell-derived TSLP, IL-25 and IL-33 after exposure to allergens, chemicals or helminth parasites, or after influenza virus infection [29] [30] [31] [32] 63, 90, [111] [112] [113] [114] [115] . Basophils can also promote pro-inflammatory ILC2 responses in the skin and lung through production of IL-4 in mouse models of chemical-induced atopic dermatitis and protease allergen-induced airway inflammation 116, 117 . Further, human mast cells co-localize near ILC2s in the human lung and could directly promote ILC2 responses in vitro through production of prostaglandin D2 (PGD2) 118 . The population expansion of ILC2s is thought to contribute to chronic inflammation through multiple mechanisms. Production of ILC2-derived IL-5 can promote the recruitment of eosinophils into the lung and skin of mice, which contributes to tissue inflammation 114 . Further, ILC2-derived IL-13 can impair mouse lung function by enhancing airway smooth muscle cell contractility, increasing epithelial cell mucus production, polarizing macrophages to an alternatively activated macrophage (AAMac) phenotype and increasing collagen deposition 110, 111 . ILC2s in mice can also promote chronic inflammation by enhancing T helper 2 cell (T H 2) responses either indirectly by IL-13-elicited migration of activated DCs to the lung draining lymph node and subsequent T H 2 cell priming 119 , or directly by major histocompatibility complex class II (MHCII)-dependent interactions with CD4 T cells 120, 121 .
ILC3s, chronic inflammation and cancer in the skin, lung and intestine. Increases in ILC3 frequencies, cell numbers and cytokine production have also been observed in individuals with chronic inflammatory diseases, including in the skin of patients with psoriasis 75, 122 , in tumors of patients with colitis-associated colon cancer 123 , or in the bronchoalveolar lavage fluid of patients with asthma 124 . In a mouse model of psoriasis, ILC3s are the dominant source of IL-17 and IL-22 in the skin and are reduced by a p40-specific monoclonal antibody 125 , which probably blocks the IL-23-mediated population expansion or activation of ILC3s. ILC3s are necessary and sufficient to induce psoriatic plaque formation in mice via production of IL-17 and IL-22 (ref. 125) (Fig. 4b) . Further, although they are normally absent in the lungs of healthy mice 31 , in a mouse model of obesity-induced asthma, ILC3s expand in response to NLRP3-dependent production of IL-1β by macrophages 124 . ILC3s were sufficient to promote IL-17-dependent airway hyper-responsiveness in this mouse model 124 (Fig. 4b) .
The role of ILC3s in promoting intestinal inflammation is more complex, given the substantial heterogeneity observed in this cell lineage, the potential lineage plasticity, and the differential gating strategies used by different groups conducting human studies. Two reports observed an increased frequency in pro-inflammatory ILC3s in intestinal tissues from individuals with IBD 126, 127 , whereas another identified increased ILC3 production of IL-22 (ref. 102). However, as described in the next section, there have been many reports of tissue-protective functions of ILC3s in mouse models of intestinal inflammation, and additional reports of decreased ILC3 frequencies in people with IBD. The different reports may be explained by the selected mouse models and the heterogeneity and potential plasticity of ILC3s, as well as by the clinical phenotypes and tissue sources of the patient populations studied. Notwithstanding this, a unique ILC3 population has a role in two innate mouse models of intestinal inflammation (Fig. 4c) . Administration of a CD40-specific monoclonal antibody or colonization with Helicobacter hepaticus in Rag1 −/− mice induces colitis that is dependent on ILCs, RORγt, IL-17A and IFN-γ (ref. 24) . The pro-inflammatory ILC3s observed in these models are largely absent in the steady state and lack expression of c-kit, and a portion of these cells co-expressed T-bet, IFN-γ and IL-17A (ref. 24) . ILCs with a similar phenotype are also observed in mice that lack the genes encoding both T-bet and Rag2 (TRUC mice); these mice are a spontaneous model of innate cell-driven intestinal inflammation 76, 128 . TRUC mice have increased IL-17A-producing ILCs relative to littermate controls, which act in synergy with DC-derived TNF to promote intestinal inflammation 76, 128 . IL-6 was also found to be a critical cytokine that promotes IL-17A production from human and mouse npg r e v i e w r e v i e w nature medicine VOLUME 21 | NUMBER 7 | JULY 2015 7 0 3
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pro-inflammatory ILC3s 127 . ILC3s can also promote intestinal inflammation indirectly. After T. gondii infection, ILC3-derived IL-22 acts on IECs to promote expression of the T H 1 cell-promoting cytokine IL-18, which leads to subsequent tissue inflammation 129 . Further, IEC production of IL-18 was also shown to be important for ILC3 production of IL-22, indicating a previously unappreciated cross-regulatory circuit modulating inflammation and ILC3 responses 129 . Some of the pro-inflammatory ILCs may arise from a loss of RORγt expression in ILC3s and an upregulation of T-bet 68, 72 . In fate-mapping mouse models, infection with Salmonella enterica or CD40-specific monoclonal antibody administration to Rag2 −/− mice resulted in the development of ILCs that lost expression of RORγt; these ILCs resemble ILC1s in expression of T-bet and IFN-γ, and they promote intestinal inflammation 76, 128 . In human samples and humanized mice this transition of RORγt + ILC3s to RORγt -ex-ILC3s is promoted by IL-12 or can be induced after experimental induction of intestinal tissue damage with DSS 51 . Consistent with these findings, one study revealed reduced frequencies of ILC3s and increased frequencies of ILC1s in intestinal tissue from individuals with IBD relative to non-IBD controls 51 . Further, unique intraepithelial ILC1s that develop independently of ILC3s were also enriched in intestinal tissues of individuals with IBD relative to non-IBD controls, and these may contribute to the development of intestinal inflammation through production of IFN-γ following administration of a CD40-specific monoclonal antibody to Rag2-deficient mice 52 . 
In the colon, ILC3s also promote colitis-associated tumor progression via production of . In a novel model of colitisassociated cancer, Rag1 −/− mice, which exhibit chronic intestinal inflammation when colonized with H. hepaticus, were administered the carcinogen azoxymethane (AOM) and found to develop colitisassociated colorectal cancer in an ILC-and IL-22-dependent manner 123 . The timing and regulation of IL-22 production is important to consider in the context of intestinal tumors, as IL-22 production during the peak of intestinal inflammation is protective against tumor formation, whereas uncontrolled IL-22 production during the resolution of inflammation promotes intestinal tumorigenesis 130 . In contrast, in an implantable model of mouse melanoma, ILCs that were previously marked with RORγt expression could promote IL-12-mediated tumor rejection 131 . In this mouse model, ILCs induced expression of adhesion molecules in the tumor vasculature, which subsequently enhanced recruitment of immune cells and anti-tumor immunity 131 , although this occurred in the context of a genetically modified tumor that overexpressed IL-12. Further, given that the characterized ILCs were previously described as expressing RORγt, the possibility remains that these anti-tumor ILC responses were mediated by ex-ILC3s that lost RORγt expression and produced IFN-γ and TNF. Further studies are required to define the role of ILCs in influencing pro-versus anti-tumor immune responses, and in particular a role for these cells in promoting intestinal inflammation in the presence of adaptive immunity is lacking. Collectively, these studies defined a complex role for ILC1s, ILC2s and pro-inflammatory ILC3s or ex-ILC3s in promoting chronic inflammation in mice and humans.
ILCs limit chronic inflammation
ILCs can also have a role in limiting chronic inflammation, either by influencing metabolic homeostasis or by directly regulating innate and adaptive immune cell responses to non-harmful environmental stimuli in the intestine, such as commensal bacteria or dietary antigens (Fig. 5 ).
ILC2s and metabolic homeostasis. ILC2s have been characterized in the intestine, lung and adipose tissues of healthy humans and mice [29] [30] [31] [32] [33] . In the intestine of mice, ILC2s control the homeostasis of circulating eosinophils through constitutive production of IL-5, and they regulate tissue-resident eosinophils in the intestine through induced production of IL-13 and subsequent eotaxin expression 132 . Tissue recruitment of eosinophils in the intestine is regulated by nutrient intake and central circadian rhythms that induce vasoactive intestinal peptide (VIP) expression by IECs, and VIP stimulates ILC2 production of IL-13 through the VPAC2 receptor 132 . However, the functional significance of ILC2-mediated regulation of eosinophil homeostasis in the intestine is poorly understood. In adipose tissue of mice, ILC2s can regulate eosinophil homeostasis and AAMac polarization 64, 65 . In obese mice fed a high-fat diet, or in obese humans, frequencies of ILC2s are reduced in the adipose tissues as compared to non-obese controls, and this reduction in ILC2s is associated with a reciprocal increase in chronic low-grade systemic inflammation [64] [65] [66] , suggesting a critical role for ILC2s in regulating metabolic homeostasis. Consistent with this, experimental depletion of ILCs exacerbates weight gain in mice and causes insulin resistance, whereas treatment 
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of mice on a high-fat diet with exogenous IL-25 or IL-33 increases ILC2 numbers and limits metabolic disease [64] [65] [66] . Mechanistically, this occurred either indirectly through recruitment of eosinophils and differentiation of AAMacs in adipose tissues, or directly by acting on adipocytes via ILC2-derived IL-13 or methionine-enkephalin peptides 66, 133 . Activation of adipocytes through these pathways induces expression of the transcription factor Ucp1 and 'beiging' of white adipocytes 66, 133 , a process which induces thermogenesis, protects against insulin resistance and regulates metabolic homeostasis 134 . Additional research is required to further define how ILC2s orchestrate metabolic homeostasis, and whether this may also involve crosstalk with other IL-33R + cells, such as recently described subsets of regulatory T (T reg ) cells [135] [136] [137] .
ILC3s in chronic systemic and intestinal inflammation. ILC3s also limit chronic inflammation through several distinct mechanisms (Fig. 5b) , which may be particularly important in the intestine, as there are several reports of reduced frequencies of ILC3s in individuals with IBD or with HIV infection relative to controls 51, 95, 96, [138] [139] [140] [141] .
In the intestine and associated lymphoid tissues of healthy humans, non-human primates and mice, ILC3s are a dominant source of IL-22 that is in part influenced by the colonization of the intestine with commensal bacteria 6, 142 . Production of IL-22 restricts the anatomical localization or replication of specific species of commensal bacteria in mice. Impairment of this pathway promotes systemic dissemination of lymphoid tissue-resident commensal bacteria or increased colonization in the intestinal epithelium with segmented filamentous bacteria, resulting in low-grade systemic and intestinal inflammation 142, 143 . This may be particularly important in the context of HIV infection and progression to AIDS, in which there are defects in intestinal barrier function such that systemic dissemination of commensal bacteria promotes chronic immune activation and contributes to viral replication, loss of CD4 + T cells and disease progression 144 . In humans and non-human primates, numbers of ILC3s and production of IL-22 are reduced in the intestine after pathogenic infection with HIV or simian immunodeficiency virus (SIV) [138] [139] [140] [141] , and thus may be a novel therapeutic target for limiting disease progression. Production of IL-22 in mice can also promote colonization of the intestine by beneficial and diverse commensal bacteria that provide protection from intestinal inflammation and infection [83] [84] [85] . This occurs via ILC3-and IL-22-dependent fucosylation or glycosylation of IECs via Fut2, thus providing a sugar food source for beneficial microbiota, which in turn limits the growth of pathogens or opportunistic pathogens and protects against intestinal tissue damage 83-85 . IL-22 production by ILC3s also requires maintained expression of Id2 and subsequent regulation of the IL-23R and Ahr pathways, which is necessary to limit infection-induced damage in mice by regulating colonization resistance and the composition of intestinal commensal bacteria 145 . ILC3s can also limit chronic inflammation through indirect and direct regulation of the adaptive immune cell response 146 (Fig. 5b) . ILCs regulate homeostasis of myeloid cells in the intestine of mice through production of granulocyte macrophage colony-stimulating factor (GM-CSF) 147 . This process is regulated by macrophage sensing of intestinal commensal bacteria and production of IL-1β, which can act on ILC3s to promote GM-CSF expression 147 . Conversely, production of GM-CSF by ILC3s was essential to modulate myeloid cells and subsequently generate T reg cell responses to food antigens in the intestine and maintain oral tolerance 147 . Through production of LTα 1 β 2 or a soluble LTα 3 , ILC3s can influence the production of T cell-independent and T cell-dependent IgA production in the intestine, respectively, which modulates the composition of the intestinal commensal bacteria 148, 149 . Human and mouse ILC3s were also found to express MHCII, process and present antigens, and directly interact with CD4 + T cells 150 . Genetic deletion of ILC3-intrisic MHCII in mice results in the development of spontaneous CD4 + T cellmediated intestinal inflammation, which was dependent on commensal bacteria 150, 151 . Mechanistically, MHCII + ILC3s induced cell death of activated commensal bacteria-specific CD4 + T cells in the intestine of mice, revealing a previously unappreciated selection pathway in the intestine whereby T cells with the potential to cause local inflammation are deleted, akin to the process that occurs for self-reactive T cells during thymic selection 152 . Although no differences were observed in the frequency of ILC3s in intestinal biopsies of pediatric IBD patients, a substantial reduction of MHCII on ILC3s was observed relative to non-IBD controls, and this reduction inversely correlated with increased intestinal T H 17 cells 152 . These studies identify an essential role for ILC3s in maintaining tissue homeostasis and limiting chronic inflammation in the intestine of humans and mice. Further studies are necessary to interrogate what causes dysregulated ILC3 numbers or responses in the context of chronic human diseases, such as HIV infection or IBD.
Potential therapeutic modulation of ILCs
Given the role of ILCs in the initiation, regulation and resolution of inflammation in mice, and in the reported alterations of ILCs in defined patient populations, there is an urgent need to investigate whether therapeutic strategies can be used to modulate ILC responses and provide clinical benefit. As a proof of principle, ILC responses were recently shown to be modulated in patients with multiple sclerosis (MS) after CD25-specific monoclonal antibody (daclizumab) therapy 153 . Although the role of ILCs in MS is poorly defined, this study identified increased circulating numbers of ILC3-like cells in individuals with MS that were reduced after CD25-specific monoclonal antibody treatment and associated with reduced inflammatory markers in the cerebrospinal fluid 153 . Despite this advance, further high-resolution profiling of ILC responses in defined patient populations, and during specific treatment regimens, is required to fully elucidate how we can modulate ILCs to limit human disease.
There are many other therapeutics in the clinic or currently under development that could influence ILC differentiation, homeostasis or function. These include targeting the cytokine-cytokine receptor pathways that are critical for the differentiation, function and maintenance of ILCs such as IL-2-IL-2R, IL-12-IL-12R, IL-23-IL-23R, IL-1-IL-1R, TSLP-TSLPR and IL-6-IL-6R; targeting molecules critical for migration of ILCs such as α4β7 and MAdCAM-1; or targeting effector molecules of ILCs such as TNF-TNFR, IL-17-IL-17R, IFNγ and IL-13-IL-13R. It will be important to consider how these strategies may influence the pathologic versus protective functions of ILCs. For example, targeting the IL-23-IL-17 pathway has demonstrated efficacy in psoriasis and rheumatoid arthritis [154] [155] [156] [157] . However, in IBD patients, blockade of IL-17 had limited efficacy and in some cases resulted in enhanced disease and susceptibility to fungal infections [158] [159] [160] [161] . Given the role of ILC3s and IL-17 in promoting anti-fungal immunity 86 , one possibility is that targeting IL-17 may have limited efficacy in certain conditions, as it also targeted protective ILC3 responses. Therefore, the design of novel therapeutics may be necessary in order to find strategies that selectively modulate protective versus pathologic ILC responses. These could include novel small-molecule inhibitors of transcription factors, other recently identified ILC modulators in mice and humans, such as the vitamin A metabolite retinoic acid, Lipoxin A4, npg r e v i e w r e v i e w 7 0 6 VOLUME 21 | NUMBER 7 | JULY 2015 nature medicine
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or exogenous cytokines that may promote protective functions of ILCs or limit their pathologic potential 81, 99, 108, 118 .
Outstanding questions and future directions
Research on the biology of ILCs has already advanced our understanding of their development and the role they have in regulating acute and chronic inflammation as well as tissue repair. One future challenge is to better define this family of innate immune cells, and to delineate how they specifically interact with other innate, adaptive and non-hematopoietic cells to promote, limit or resolve inflammation. A universal consensus on gating strategies on human and mouse ILCs should be considered. A critical evaluation of translational studies is needed, and it should be focused on examining patient numbers, current medication use, longitudinal samples, sources of healthy or non-diseased control tissues, tissue digestion protocols, and genetic and environmental factors such as commensal bacteria. Further, additional mouse studies are needed to carefully define the potential plasticity of ILC populations, and to identify novel functions and regulatory pathways influencing ILC responses. Defining these outstanding questions could prompt the development of novel therapeutic strategies or promote new approaches that will permit selective regulation of protective versus pathologic ILC responses. These advances will be critical for our understanding of the cellular and molecular basis of inflammation and to determining whether and how we can manipulate ILC responses to maintain healthy tissues and limit chronic inflammation.
r e v i e w r e v i e w 7 0 8 VOLUME 21 | NUMBER 7 | JULY 2015 nature medicine
